ECO Animal Health Group said on Monday that its subsidiary ECO Animal Health do Brasil, has received a marketing authorisation from the Brazilian Ministry of Agriculture, Livestock and Supply (MAPA) for the use of swine disease medicine Aivlosin 625 mg/g water soluble granules in swine.
Aivlosin, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
This formulation of Aivlosin will be marketed for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric swine disease. Aivlosin water soluble granules dissolve readily in water providing a simple solution for the accurate and simultaneous treatment of large numbers of animals. Importantly, with global concerns about the use of antibiotics in production animals, this new treatment with its low therapeutic dose rate and short treatment duration meets antimicrobial stewardship guidelines.
Peter Lawrence, Chairman of ECO, commented “This approval from the Brazilian MAPA is very important in the development of Aivlosin for swine globally. Brazil is one of the world’s leading producers and exporters of pork and this new formulation will enhance our ability to offer an expanded range of valuable therapeutic tools to swine producers for both the domestic and export markets”.